The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis

• Published in: Critical reviews in oncology/hematology Vol. 116; pp. 134 - 146
• Main Authors: Dolan, Ross D, McSorley, Stephen T, Horgan, Paul G, Laird, Barry, McMillan, Donald C
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2017
• Subjects: Advanced cancer; Albumin; Animals; Biomarkers, Tumor - metabolism; C-reactive protein; Disease specific survival; Glasgow prognostic score; Hematology, Oncology and Palliative Medicine; Humans; Inflammation - diagnosis; Inflammation - etiology; Inflammation - metabolism; Lymphocyte count; Monocyte count; Neoplasms - complications; Neoplasms - metabolism; Neutrophil count; Neutrophil lymphocyte ratio; Overall survival; Platelet count; Platelet lymphocyte ratio; Prognosis; Systemic inflammation; White cell count; Glasgow prognostic score; C-reactive protein; Albumin; White cell count; Neutrophil count; Advanced cancer; Lymphocyte count; Platelet lymphocyte ratio; Monocyte count; Neutrophil lymphocyte ratio; Overall survival; Disease specific survival; Systemic inflammation; Platelet count
• DOI: 10.1016/j.critrevonc.2017.06.002
• ISSN: 1040-8428; 1879-0461

•Provides comprehensive evidence for the prognostic role of the SIR in advanced cancer.•This review will prove to be clinically very useful in guiding evidence based patient care.•Including surgical and oncological treatments. Cancer remains a leading cause of death worldwide. While a curative intent is the aim of any surgical treatment many patients either present with or go onto develop disseminated disease requiring systemic anti-cancer therapy with a palliative intent. Given their limited life expectancy appropriate allocation of treatment is vital. It is recognised that systemic chemoradiotherapy may shorten the quality/quantity of life in patients with advanced cancer. It is against this background that the present systematic review and meta-analysis of the prognostic value of markers of the systemic inflammatory response in patients with advanced cancer was conducted. An extensive literature review using targeted medical subject headings was carried out in the MEDLINE, EMBASE, and CDSR databases until the end of 2016. Titles were examined for relevance and studies relating to duplicate datasets, that were not published in English and that did not have full text availability were excluded. Full texts of relevant articles were obtained and were then examined to identify any further relevant articles. The majority of studies were retrospective. The systemic inflammatory response, as evidenced by a number of markers at clinical thresholds, was reported to have independent prognostic value, across tumour types and geographical locations. In particular, C-reactive protein (CRP, 63 studies), albumin (33 studies) the Glasgow Prognostic Score (GPS, 44 studies) and the Neutrophil Lymphocyte Ratio (NLR, 59 articles) were consistently validated across tumour types and geographical locations. There was considerable variation in the thresholds reported to have prognostic value when CRP and albumin were examined. There was less variation in the thresholds reported for NLR and still less for the GPS. The systemic inflammatory response, especially as evidenced by the GPS and NLR, has reliable prognostic value in patients with advanced cancer. Further prospective studies of their clinical utility in randomised clinical trials and in treatment allocation are warranted.